Autoantibodies to thrombopoietin (TPO, also termed THPO) or the TPO receptor (cMpl, also termed MPL) could play a pathological role in immune thrombocytopenia (ITP). In this study, we tested for autoantibodies against TPO, cMpl, or the TPO/cMpl complex in ITP and other thrombocytopenic disorders. Using an inhibition step with excess TPO in fluid-phase to improve binding specificity, the prevalence of anti-TPO autoantibodies was: active ITP: 9/32 (28%); remission ITP: 0/14 (0%); non-immune thrombocytopenias: 1/10 (10%); and healthy controls: 1/11 (9%). Similarly, using an inhibition step with excess cMpl, the prevalence of specific anti-cMpl autoantibodies was: active ITP: 7/32 (22%); remission ITP: 1/14 (7%); non-immune thrombocytopenias: 3/10 (30%); and healthy controls: 0/11 (0%). Two active ITP patients had autoantibodies against the TPO/cMpl complex, but not against TPO or cMpl alone. Anti-TPO or anti-cMpl autoantibodies were found in 44% of ITP patients, and in 40% of patients with other thrombocytopenic disorders. These autoantibodies did not correlate with ITP disease severity or number of ITP treatments received; however, in this cohort, 3 patients failed to respond to TPO receptor agonist medications, and of those, 2 had anti-TPO autoantibodies. This suggests that anti-TPO and anti-cMpl autoantibodies are associated with thrombocytopenia, and may be clinically relevant in a subset of ITP patients.
Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder characterized by low platelet counts in the absence of other causes (Rodeghiero et al, 2009) . The clinical presentation of ITP is variable, ranging from asymptomatic thrombocytopenia to life threatening bleeding (Neunert et al, 2015) . Therapy is aimed at maintaining a safe platelet count level to prevent bleeding complications (Arnold & Kelton, 2007) . Many patients with ITP will achieve a transient response to first or second line therapies, including corticosteroids, intravenous immune globulin (IVIg) and splenectomy, but the course of the disease is chronic in approximately two-thirds of adult cases. Patients with refractory ITP who do not respond to treatments can have a fourfold increased risk of death [95% confidence interval (CI) 1Á7-10Á0] (Berchtold & McMillan, 1989; Cohen et al, 2000; Portielje et al, 2001; Mahevas et al, 2016) . A better understanding of the pathogenesis of ITP could lead to more effective, targeted treatments. Increasingly, evidence suggests that primary ITP is a heterogeneous disease that may represent a group of disorders with different mechanisms, each leading to the development of thrombocytopenia (Shih et al, 2014) .
The prevailing hypothesis to explain ITP is the presence of autoantibodies that target major platelet glycoproteins (GP). These autoantibodies can lead to platelet destruction in the reticuloendothelial system (RES) (McMillan, 2003) or platelet underproduction by targeting megakaryocytes in the bone marrow (Lev et al, 2014) . However, anti-GPIIbIIIa and antiGPIbIX autoantibodies are detectable in only 40-60% of ITP patients, even when sensitive techniques are used (Beardsley et al, 1984; McMillan et al, 1987; Warner et al, 1999; McMillan, 2003 McMillan, , 2005 , raising the possibility that other specificities of platelet-related autoantibodies are important. Identification of these autoantibodies could elucidate mechanisms, improve diagnosis and, potentially, predict clinical outcomes. Previous studies have shown that some patients with ITP have autoantibodies against thrombopoietin [TPO; HUGO Gene Nomenclature Committee (HGNC) symbol: THPO] or its receptor (cMpl, HGNC: MPL) (Fureder et al, 2002; Kuwana et al, 2002; Aledort et al, 2004; Ziakas et al, 2008) . Given that both platelets and megakaryocytes express cMpl, it is possible that anti-TPO or anti-cMpl autoantibodies could contribute to platelet destruction and platelet underproduction in patients with ITP.
In this report, we describe the development of assays used to measure autoantibodies against TPO, cMpl and the complex formed by TPO bound to cMpl, and the application of these assays to ITP patients and thrombocytopenic controls. Patients were identified from a prospective longitudinal registry of well-characterized patients with ITP and nonimmune thrombocytopenia from other causes.
Material and methods

Patients
Patients with thrombocytopenia were identified from the McMaster ITP Registry, a longitudinal study of consecutive adult patients referred to a tertiary haematology clinic for evaluation of a low platelet count (Arnold et al, 2017) . Clinical information was collected prospectively, and platelet lysates and sera were frozen and stored for autoantibody investigations. The diagnosis of primary ITP was determined by 2 haematologists working together in the clinic using established criteria: isolated thrombocytopenia (platelet count <100 9 10 9 /l) with no other cause, and no secondary cause of immune thrombocytopenia identified (Neunert et al, 2011) . We excluded patients with hepatitis C, human immunodeficiency virus or H. pylori infection; patients with a positive anti-nuclear antibody, direct antiglobulin test or antiphospholipid antibody test; and patients who had received immunemodulating therapies during the previous 3 months. We compared the prevalence of the autoantibodies in patients with active ITP (platelet count <100 9 10 9 /l), ITP in remission (platelet count >100 9 10 9 /l for at least 3 months after having a platelet count <100 9 10 9 /l) and patients with nonimmune thrombocytopenia from other causes, including myelodysplastic syndrome (MDS; confirmed by bone marrow morphology and cytogenetics), splenomegaly (with documented splenic enlargement on imaging), or familial thrombocytopenia (based on a compatible clinical presentation and positive family history). This study was approved by the Hamilton Integrated Research Ethics Board (HIREB) and all participants provided informed consent.
Autoantibodies to TPO and cMpl
Platelet-poor plasma was obtained from whole blood samples by differential centrifugation and stored at À70°C until testing. Enzyme immunoassays (EIA) for circulating anti-TPO and anti-cMpl autoantibodies were developed, based on established methods (Horsewood et al, 1996 The reproducibility of these assays was confirmed by repeat testing (n = 2 separate experiments) for anti-TPO and anti-cMpl autoantibodies using ITP samples (n = 4) and healthy controls (n = 2). In addition, we used a pooled normal sample (n = 10 donors) as a control for every experiment.
Autoantibodies to the TPO/cMpl complex
We investigated the presence of autoantibodies that specifically recognized the antigenic complex formed by TPO bound to its receptor, cMpl. To confirm complex formation, a 96-well microtiter plate was coated with 100 ll of recombinant human cMpl (5 lg/ml) in bicarbonate buffer and incubated at 4°C overnight. After washing and blocking, 100 ll of recombinant human TPO (2Á5 lg/ml) was added to each well and incubated for 2 h at RT. The presence of complexed TPO was confirmed using an anti-human TPO polyclonal antibody and measuring the OD 405 nm . Similar experiments were done in reverse order, using TPO to coat the plates, and an anti-human cMpl polyclonal antibody to confirm complexed cMpl.
In the testing assay for autoantibodies against the TPO/ cMpl complex, we coated microtiter plates with 100 ll of recombinant human cMpl (5 lg/ml) in bicarbonate buffer and incubated at 4°C overnight. After washing and blocking, Platelet Autoantibodies in Immune Thrombocytopenia ª 2018 John Wiley & Sons Ltd 100 ll of recombinant human TPO (2Á5 lg/ml) was added to each well and incubated for 2 h at RT. The plate was then blocked, washed and patient samples were added to each well (1:25 dilution) with 1% BSA/PBS for 2 h at RT. The OD 405 nm was measured after the addition of p-NPP. A positive value was defined as an OD 405 nm > 0Á3 based on the mean AE 2 SD of the results obtained using samples from healthy individuals.
Specificity of Autoantibody Binding
A fluid-phase inhibition step was used to confirm the specificity of anti-TPO, anti-cMpl and anti-TPO/cMpl autoantibodies. For the TPO and cMpl EIAs, an equal volume of 20 lg/ml of TPO or 20 lg/ml of cMpl was added to an equal volume of 1:12Á5 sample (final 10 lg/ml inhibitor and 1:25 sample). After incubating for 1 h at RT, 100 ll of the mixture was added to wells coated with the respective antigen and binding of TPO or cMpl autoantibodies was measured. For the TPO/cMpl complex, the combined antigen was formed in fluid-phase and then added to samples with anti-TPO/cMpl autoantibodies. Autoantibodies were considered inhibitable if the OD 405 nm was reduced by >50% or below the positive cutoff (OD 405 nm = 0Á3) with the addition of excess antigen. Saturating concentrations (20 lg/ml) of fluid-phase inhibitors were used, as determined by doseresponse curves (data not shown).
Platelet-bound autoantibodies against GPIIb/IIIa and GPIb/IX
Platelet bound anti-GPIIb/IIIa and anti-GPIb/IX autoantibodies were measured using a modified antigen capture assay, previously described (McMillan et al, 1987; Kelton, 1995; Arnold et al, 2012) . Whole blood from patients were collected into acid citrate dextrose (ACD, 6:1, v/v) and processed within 24 h of collection. Platelets were harvested after differential centrifugation, washed and resuspended at 300 9 10 9 /l in lysing buffer containing 1% Triton X-100, 0Á1% sodium dodecyl sulphate (SDS) and protease inhibitors (Roche, Indianapolis, IN, USA). Platelet lysates were stored at À70°C until testing. Microtiter wells were coated with 100 ll goat anti-mouse IgG, Fc fragment-specific (10 lg/ml) at 4°C overnight and followed by 100 ll of in-house, monoclonal anti-GPIIb/IIIa (Raj-1, 10 lg/ml) or anti-GPIb/IX (TW-1, 10 lg/ml) (Horsewood et al, 1991) with overnight incubation at 4°C. After blocking, 50 ll of platelet lysate was added in duplicate and incubated for 2 h at RT. Bound anti-GPIIb/IIIa or anti-GPIb/IX was measured using alkaline phosphatase-conjugated goat anti-human IgG, Fc specific (Jackson ImmunoResearch Laboratories, West Grove, PA, USA). A positive result was defined as an optical density at 450 nm (OD 405 nm ) > 0Á21 based on the mean AE 2 standard deviations (SD) of healthy individuals (n = 30).
Statistical analysis
Platelet counts and number of treatments received were described in patients with and without detectable antibodies. We compared groups using nonparametric median tests to examine whether two independent samples had the same median. This test provided a P-value, which was calculated by Chi-Square statistic; P < 0Á05 was considered statistically significant. The 95% CI for each proportion was calculated by Wilson-Score method.
Results
Patients
Patients with active primary ITP (n = 32) had a median platelet count of 42 9 10 9 /l [interquartile range (IQR) 20-61 9 10 9 /l] at the time of testing. Median age was 47Á3 years and 56% were female. Patients had ITP for a median of 11Á8 years (IQR 1Á6-14Á0) and had received a median of 2 prior ITP treatments (IQR 0-3) ( Table I ). ITP patients in remission (n = 14) had a median platelet count of 168 9 10 9 /l (IQR 118-208 9 10 9 /l) and had received a median of 3 prior treatments (IQR 2-4). Patients with other causes of thrombocytopenia had MDS (n = 3), hypersplenism (n = 5) or familial thrombocytopenia (n = 2). Median platelet count was 86 9 10 9 /l (IQR 57-102 9 10 9 /l).
Autoantibody detection
On initial testing, autoantibodies to anti-TPO were detectable in 16/32 (50%) patients with active ITP, 6/14 (42Á9%) ITP patients in remission, 5/10 (50%) patients with other thrombocytopenic disorders and 7/11 (63Á6%) healthy controls. To improve the specificity of the assay, we added the inhibition step using excess fluid-phase antigen, and defined a positive result as inhibition by >50% or a post-inhibition result that was below the positive cut-off (OD 405 nm = 0Á3). Using these criteria, specific anti-TPO autoantibodies were detected in 9/ 32 (28Á1%) patients with active ITP, 0% patients with ITP in remission, 1/10 (10%) patients with other thrombocytopenic disorders (familial thrombocytopenia) and 1/11 (9Á1%) healthy controls (Fig 1A) . For anti-cMpl, specific, inhibitable autoantibodies were detected in 7/32 (21Á8%) patients with active ITP, 1/14 (7Á1%) patients in remission and 3/10 (30%) patients with other thrombocytopenic disorders, including splenomegaly (n = 1), familial thrombocytopenia (n = 1) and MDS (n = 1), and 0% of healthy controls (Fig 1B) . We identified 2 (6Á3%) patients with active ITP who had autoantibodies to the TPO/cMpl complex (OD 405 nm = 0Á4, 0Á7) that did not bind either to TPO or cMpl alone; both were inhibitable with excess TPO/cMpl complex in the fluid phase (OD 405 nm = 0Á1 and 0Á1) but not with excess TPO (OD 405 nm = 0Á3 and 0Á5) or cMpl (OD 405 nm = 0Á3 and 0Á6). Anti-TPO/cMpl autoantibodies were not detected in patients in remission or in controls. Overall, 14/32 (43Á8%) of patients with active ITP had specific autoantibodies to any of these antigens (Table II) .
We also investigated for platelet-bound autoantibodies to GPIIb/IIIa and GPIb/IX. These autoantibodies were detected in 13/32 (40Á6%) patients with active ITP, 6/14 (42Á9%) ITP patients in remission and 1/10 (10%) patients with thrombocytopenia from non-immune causes (familial thrombocytopenia) (Table II) .
Clinical comparisons
We identified 5 patients in this cohort who had received TPO receptor agonist medications: 3 failed to respond and of those, 2 had anti-TPO autoantibodies. The other 2 patients responded to treatment and neither patient had anti-TPO or anti-cMpl autoantibodies. We identified 3 patients who had received rituximab. Two patients responded and both had autoantibodies (anti-TPO and antiGPIbIX in one patient, anti-GPIIbIIIa in the other). One patient, who had anti-TPO and anti-GPIbIX autoantibodies, did not respond to rituximab.
Median platelet counts among patients with active ITP patients were not different in those with anti-TPO, anti-cMpl or anti-TPO/cMpl autoantibodies, compared with anti- Inhibition studies using excess antigen in fluid phase to determine binding specificity of (A) anti-TPO and (B) anti-cMpl from patients with active ITP, and patients with non-immune thrombocytopenia from other causes using enzyme immunoassays. Autoantibodies were considered specific if the OD 405 nm was reduced by >50% or dropped below the positive cut-off (OD 405 nm = 0Á3) with the addition of excess antigen. cMpl, thrombopoietin receptor; ITP, immune thrombocytopenia; OD 405 nm , optical density at 405 nm; TPO, thrombopoietin.
GPIIb/IIIa or anti-GPIb/IX autoantibodies (46 9 10 9 /l, IQR 6-80 9 10 9 /l; vs. 42 9 10 9 /l, IQR 21-58 9 10 9 /l) (Fig 2A) .
Similarly, median platelet counts were not different in active ITP patients who were autoantibody-positive (any autoantibody) or autoantibody-negative (42 9 10 9 /l, IQR 8Á5-63Á5 9 10 9 /l; vs. 47 9 10 9 /l, IQR 36-58 9 10 9 /l) ( Fig 2C) . The number of prior treatments received by patients with active ITP with only anti-TPO, anti-cMpl or Table II . Autoantibodies against TPO, cMpl, and TPO/cMpl complex in patients with active ITP (n = 32), ITP in remission (n = 14), nonimmune thrombocytopenia (n = 10) and healthy controls (n = 11). Only specific autoantibodies that were inhibitable with excess antigen are reported. Remission = platelet count >100 9 10 9 /l for at least 3 months after having active disease (with platelet counts below 100 9 10 9 /l). Results are given as number of patients (n), with 95% confidence intervals.
Non-immune thrombocytopenia (n = 10) Healthy controls (n = 11) Anti-TPO 9 (28Á1%; 15Á6-45Á4%) 0 (0%; 0-21Á5%) 1 (10%; 1Á8-40Á4%) 1 (9Á1%; 1Á6-37Á7%) Anti-cMpl 7 (21Á9%; 11-38Á8%) 1 (7Á1%; 1Á3-31Á5%) 3 (30%; 10Á8-60Á3%) 0 (0%; 0-25Á9%) Anti-TPO/cMpl complex 2 (6Á2%; 1Á7-20Á1%) 0 (0%; 0-21Á5%) 0 (0%; 0-27Á8%) 0 (0%; 0-25Á9%) Anti-TPO and anti-cMpl 4 (12Á5%; 5-28Á1%) 0 (0%; 0-21Á5%) 0 (0%; 0-27Á8%) 0 (0%; 0-25Á9%) Anti-TPO, anti-cMpl or anti-TPO/cMpl 14 (43Á8%; 28Á2-60Á7%) 1 (7Á1%; 1Á3-31Á5%) 4 (40%; 16Á8-68Á7%) 1 (9Á1%; 1Á6-37Á7%)
Anti-GPIIb/IIIa or anti-GPIb/IX 13 (40Á6%; 25Á5-57Á7%) 6 (42Á9%; 21Á4-67Á4%) 1 (10%; 1Á8-40Á4%) 0 (0%; 0-25Á9%) Any autoantibody 23 (71Á9%; 54Á6-84Á4%) 7 (50%; 26Á8-73Á2%) 4 (40%; 16Á8-68Á7%) 1 (9Á1%; 1Á6-37Á7%) cMpl, thrombopoietin receptor; GP, glycoprotein; ITP, immune thrombocytopenia; TPO, thrombopoietin. anti-TPO/cMpl was not different compared with patients who had anti-GPIIb/IIIa or anti-GPIb/IX (median 1, IQR 0-3; vs. median 2, IQR 1-4) (Fig 2B) . Similarly, the number of prior treatments was not different in patients with or without an autoantibody (median 2, IQR 0-4; vs. median 1, IQR 0-2) (Fig 2D) . Thus, the presence of autoantibodies did not correlate with severity of the thrombocytopenia or the number of previous treatments.
anti-cMpl anti-TPO
Discussion
In this study, we measured autoantibodies directed against TPO, its receptor (cMpl), and the complex formed by TPO bound to cMpl. We found that these autoantibodies were detectable in 44% of patients with active ITP, but also in 40% of patients with non-immune causes of thrombocytopenia. For the first time, we found conformation-dependent autoantibodies against the complex of TPO bound to its receptor cMpl, which did not react with either TPO or cMpl alone. These autoantibodies were present in 2 patients with active ITP only. By incorporating an inhibition step with excess antigen, we were able to improve antibody specificity, as has been reported previously for anti-TPO (Aledort et al, 2004) and other autoantibodies (Guven et al, 2014) ; however, even with that additional step, their detection was not restricted to ITP patients. ITP is a common autoimmune disorder with no specific diagnostic test. For some patients, the diagnosis can be clinically obvious, but for others, establishing the diagnosis can be challenging (Shih et al, 2014; Salib et al, 2016) . Furthermore, the pathological mechanisms leading to thrombocytopenia in patients with primary ITP remains elusive. This leads to misdiagnosis, which has been shown to occur in as many as one in 7 patients (Arnold et al, 2017) , and excess toxicities from inappropriate treatments. We proposed that autoantibodies other than anti-GPIIb/IIIa and anti-GPIb/IX might be important, since these latter autoantibodies are known to be present in only 40-60% of patients (Beardsley et al, 1984; McMillan et al, 1987 McMillan et al, , 2003 Brighton et al, 1996; Warner et al, 1999; McMillan, 2003 McMillan, , 2005 . Thus, we investigated anti-TPO and anti-cMpl autoantibodies because they have the potential to bind megakaryocytes, interfere with megakaryocyte growth and interfere with platelet production.
Anti-TPO autoantibodies have been previously found in approximately one-third of patients with systemic lupus erythematosus (SLE) and thrombocytopenia (Fureder et al, 2002; Ziakas et al, 2006 Ziakas et al, , 2008 . In another study, only 1% of primary ITP patients (n = 205) had anti-TPO autoantibodies (Aledort et al, 2004) . Autoantibodies against cMpl have also been detected in 11Á6% of SLE patients (n = 69) and 8Á3% of ITP patients (n = 84) (Kuwana et al, 2002) . Our results suggest that these autoantibodies may be collateral markers of thrombocytopenia rather than causally related to ITP mechanisms. On the other hand, we found that 2 of 3 patients who had failed TPO receptor agonist treatment had anti-TPO antibodies, raising the possibility that they may be clinically relevant in a subset of ITP patients. Further studies are needed to differentiate functional and non-functional autoantibodies, similar to patients with antiphospholipid syndrome.
We identified novel autoantibodies that were specific for a neoantigen formed by the TPO/cMpl complex. Conformational-dependence is a recognized feature of other platelet antibodies in drug-induced immune thrombocytopenia (Von Drygalski et al, 2007) and heparin-induced thrombocytopenia (Horsewood et al, 1996; Ziporen et al, 1998; Li et al, 2002) . Although anti-TPO/cMpl autoantibodies were detected in only 2 patients, both had active ITP, suggesting that this observation may be clinically important.
Within the group of active ITP patients, the severity of thrombocytopenia did not correlate with the presence of autoantibodies, and clinical features were similar for patients with anti-TPO, anti-cMpl or anti-TPO/cMpl autoantibodies compared with anti-GPIIb/IIIa or anti-GPIb/IX autoantibodies. By contrast, previous investigators have reported that anti-TPO or anti-cMpl autoantibodies were associated with more severe disease (Kuwana et al, 2002; Ziakas et al, 2006 Ziakas et al, , 2008 or poor responses to treatments (Kuwana et al, 2006) .
Strengths of this study were the use of thrombocytopenic controls, avoidance of the confounding effects of recent exposure to immune modulating treatments, and the discovery of autoantibodies against the TPO/cMpl complex. Limitations were the retrospective study design, small sample size and lack of functional characterization of the autoantibodies. This study does not consider other mechanisms of thrombocytopenia, which are likely to be important in some ITP patients, including T cell cytotoxicity against platelets or megakaryocytes (Zhao et al, 2008; Zhou et al, 2014; Qiu et al, 2016) .
Our results expand the repertoire of autoantibodies that may be related to the development of thrombocytopenia and highlight the importance of using thrombocytopenic controls in experimental studies of ITP. Further research is needed to determine the functional effect of these autoantibodies and their utility in classifying patients with thrombocytopenia.
